Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 5/2019

27.02.2019 | Original Article

Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model

verfasst von: Daniel Thorpe, Masooma Sultani, Andrea Stringer

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Irinotecan-induced mucositis is a major oncological problem. Goblet cells secrete mucus, protecting the intestinal mucosa, with secretion altered during mucositis. The enteric nervous system is involved in regulating gut motility and secretion. The aim of this study was to determine whether enteric neural cells and goblet cells are altered following irinotecan treatment. Tumour-bearing Dark Agouti rats were administered a single dose of 175 mg/kg of irinotecan intraperitoneally and 0.01 mg/kg atropine subcutaneously. Experimental and untreated control rats were killed at times 6, 24, 48, 72, 96 and 120 h after treatment. Jejunum and colon samples were formalin fixed. Haematoxylin and eosin staining, Alcian Blue–PAS staining, and immunohistochemistry with S-100 antibody (neural cell marker) were carried out. Statistical analyses were carried out using Kruskal–Wallis test with Dunns post test, Mann Whitney U test, and nonlinear regression. Total goblet cells decreased at 72 h compared with controls in the colon (p < 0.05). The percentage of cavitated goblet cells decreased compared to all other time points at 120 h in the colon. The number of S-100-positive cells in the submucosal plexus decreased in the colon (p = 0.0046) and in the myenteric plexus of the jejunum and colon (p = 0.0058 and p = 0.0022, respectively), on comparing treated with control. Enteric ganglia in the myenteric plexus of the jejunum decreased at 24 h and 96 h. Irinotecan-induced mucositis is associated with increases in mucus secretion and enteric neural cell change. These changes may contribute to the pathophysiology of mucositis through the dysregulation of neural signalling.
Literatur
1.
Zurück zum Zitat Bowen JM, Gibson RJ, Cummins AG, Tyskin A, Keefe DM (2007) “Irinotecan changes gene expression in the small intestine of the rat with breast cancer”. Cancer Chemother Pharmacol 59(3):337–348CrossRefPubMed Bowen JM, Gibson RJ, Cummins AG, Tyskin A, Keefe DM (2007) “Irinotecan changes gene expression in the small intestine of the rat with breast cancer”. Cancer Chemother Pharmacol 59(3):337–348CrossRefPubMed
2.
Zurück zum Zitat Bowen JM, Gibson RJ, Keefe DM, Cummins AG (2005) Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37(1):56–62CrossRefPubMed Bowen JM, Gibson RJ, Keefe DM, Cummins AG (2005) Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37(1):56–62CrossRefPubMed
3.
Zurück zum Zitat Branka JE, Vallette G, Jarry A, Laboisse CL (1997) Stimulation of mucin exocytosis from human epithelial cells by nitric oxide: evidence for a cGMP-dependent and a cGMP-independent pathway. Biochem J 323(Pt 2):521–524CrossRefPubMedPubMedCentral Branka JE, Vallette G, Jarry A, Laboisse CL (1997) Stimulation of mucin exocytosis from human epithelial cells by nitric oxide: evidence for a cGMP-dependent and a cGMP-independent pathway. Biochem J 323(Pt 2):521–524CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Carraway KL, Perez A, Idris N, Jepson S, Arango M, Komatsu M, Haq B, Price-Schiavi SA, Zhang J, Carraway CA (2002) Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol 71:149–185CrossRefPubMed Carraway KL, Perez A, Idris N, Jepson S, Arango M, Komatsu M, Haq B, Price-Schiavi SA, Zhang J, Carraway CA (2002) Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol 71:149–185CrossRefPubMed
5.
Zurück zum Zitat Cohen J (2013) Statistical power analysis for the behavioral sciences. Taylor and Francis, LondonCrossRef Cohen J (2013) Statistical power analysis for the behavioral sciences. Taylor and Francis, LondonCrossRef
6.
Zurück zum Zitat de Koning BA, Sluis M, Lindenbergh-Kortleve DJ, Velcich A, Pieters R, Buller HA, Einerhand AW, Renes IB (2007) Methotrexate-induced mucositis in mucin 2-deficient mice. J Cell Physiol 210(1):144–152CrossRefPubMed de Koning BA, Sluis M, Lindenbergh-Kortleve DJ, Velcich A, Pieters R, Buller HA, Einerhand AW, Renes IB (2007) Methotrexate-induced mucositis in mucin 2-deficient mice. J Cell Physiol 210(1):144–152CrossRefPubMed
7.
Zurück zum Zitat Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy. Clinical economic outcomes of chemotherapy-induced mucositis. Cancer 98(7):1531–1539CrossRefPubMed Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy. Clinical economic outcomes of chemotherapy-induced mucositis. Cancer 98(7):1531–1539CrossRefPubMed
8.
Zurück zum Zitat Elting LS, Cooksley CD, Chambers MS, Garden AS (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68(4):1110–1120CrossRef Elting LS, Cooksley CD, Chambers MS, Garden AS (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68(4):1110–1120CrossRef
9.
Zurück zum Zitat Gibson RJ, Bowen JM, Alvarez E, Finnie J, Keefe DM (2007) Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 53(5):360–369CrossRefPubMed Gibson RJ, Bowen JM, Alvarez E, Finnie J, Keefe DM (2007) Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 53(5):360–369CrossRefPubMed
10.
Zurück zum Zitat Gibson RJ, Bowen JM, Keefe DM (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 116(3):464–470CrossRefPubMed Gibson RJ, Bowen JM, Keefe DM (2005) Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 116(3):464–470CrossRefPubMed
11.
Zurück zum Zitat Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ, Edwards BG, Cummins AG (2002) The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 50(1):53–58CrossRefPubMed Gibson RJ, Keefe DM, Clarke JM, Regester GO, Thompson FM, Goland GJ, Edwards BG, Cummins AG (2002) The effect of keratinocyte growth factor on tumour growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 50(1):53–58CrossRefPubMed
12.
Zurück zum Zitat Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ, Cummins AG (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47(12):2751–2757CrossRefPubMed Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ, Cummins AG (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47(12):2751–2757CrossRefPubMed
14.
Zurück zum Zitat Keefe DM (2004) Gastrointestinal mucositis: a new biological model. Support Care Cancer 12(1):6–9CrossRefPubMed Keefe DM (2004) Gastrointestinal mucositis: a new biological model. Support Care Cancer 12(1):6–9CrossRefPubMed
15.
Zurück zum Zitat Keefe DM, Brealey J, Goland GJ, Cummins AG (2000) Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47(5):632–637CrossRefPubMedPubMedCentral Keefe DM, Brealey J, Goland GJ, Cummins AG (2000) Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47(5):632–637CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE (1997) Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 92(4):385–389CrossRef Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE (1997) Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 92(4):385–389CrossRef
17.
Zurück zum Zitat Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention treatment of mucositis. Cancer 109(5):820–831CrossRefPubMed Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention treatment of mucositis. Cancer 109(5):820–831CrossRefPubMed
18.
19.
Zurück zum Zitat Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY (2009) Macrophage-derived interleukin-6 up-regulates MUC1, but down-regulates MUC2 expression in the human colon cancer HT-29 cell line. Cell Immunol 256(1–2):19–26CrossRefPubMed Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY (2009) Macrophage-derived interleukin-6 up-regulates MUC1, but down-regulates MUC2 expression in the human colon cancer HT-29 cell line. Cell Immunol 256(1–2):19–26CrossRefPubMed
20.
Zurück zum Zitat Lima-Junior RC, Figueiredo AA, Freitas HC, Melo ML, Wong DV, Leite CA, Medeiros RP, Marques-Neto RD, Vale ML, Brito GA, Oria RB, Souza MH, Cunha FQ, Ribeiro RA (2012) Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol 69(4):931–942CrossRefPubMed Lima-Junior RC, Figueiredo AA, Freitas HC, Melo ML, Wong DV, Leite CA, Medeiros RP, Marques-Neto RD, Vale ML, Brito GA, Oria RB, Souza MH, Cunha FQ, Ribeiro RA (2012) Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol 69(4):931–942CrossRefPubMed
21.
Zurück zum Zitat Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM (2008) Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 7(7):1139–1145CrossRefPubMed Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM (2008) Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 7(7):1139–1145CrossRefPubMed
22.
Zurück zum Zitat Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM (2009) Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63(2):239–251CrossRefPubMed Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM (2009) Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63(2):239–251CrossRefPubMed
24.
Zurück zum Zitat Ollenschlager G, Thomas W, Konkol K, Diehl V, Roth E (1992) Nutritional behaviour and quality of life during oncological polychemotherapy: results of a prospective study on the efficacy of oral nutrition therapy in patients with acute leukaemia. Eur J Clin Invest 22(8):546–553CrossRefPubMed Ollenschlager G, Thomas W, Konkol K, Diehl V, Roth E (1992) Nutritional behaviour and quality of life during oncological polychemotherapy: results of a prospective study on the efficacy of oral nutrition therapy in patients with acute leukaemia. Eur J Clin Invest 22(8):546–553CrossRefPubMed
25.
Zurück zum Zitat Pfaffl MW (2004) Quantification strategies in real-time PCR. In: Bustin S (ed) A-Z of quantitative PCR. International University Line, La Jolla, pp 87–112 Pfaffl MW (2004) Quantification strategies in real-time PCR. In: Bustin S (ed) A-Z of quantitative PCR. International University Line, La Jolla, pp 87–112
26.
Zurück zum Zitat Pico JL, Avila-Garavito A, Naccache P (1998) Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3(6):446–451PubMed Pico JL, Avila-Garavito A, Naccache P (1998) Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3(6):446–451PubMed
27.
Zurück zum Zitat Plaisancie P, Barcelo A, Moro F, Claustre J, Chayvialle JA, Cuber JC (1998) Effects of neurotransmitters, gut hormones, and inflammatory mediators on mucus discharge in rat colon. Am J Physiol 275(5 Pt 1):G1073–G1084PubMed Plaisancie P, Barcelo A, Moro F, Claustre J, Chayvialle JA, Cuber JC (1998) Effects of neurotransmitters, gut hormones, and inflammatory mediators on mucus discharge in rat colon. Am J Physiol 275(5 Pt 1):G1073–G1084PubMed
28.
Zurück zum Zitat Robbe C, Capon C, Coddeville B, Michalski JC (2004) Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J 384(Pt 2):307–316CrossRefPubMedPubMedCentral Robbe C, Capon C, Coddeville B, Michalski JC (2004) Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J 384(Pt 2):307–316CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Robertson AM, Wright DP (1997) Bacterial glycosulphatases and sulphomucin degradation. Can J Gastroenterol 11(4):361–366CrossRefPubMed Robertson AM, Wright DP (1997) Bacterial glycosulphatases and sulphomucin degradation. Can J Gastroenterol 11(4):361–366CrossRefPubMed
30.
Zurück zum Zitat Saegusa Y, Ichikawa T, Iwai T, Goso Y, Ikezawa T, Nakano M, Shikama N, Saigenji K, Ishihara K (2008) Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol 43(5):531–537CrossRefPubMedPubMedCentral Saegusa Y, Ichikawa T, Iwai T, Goso Y, Ikezawa T, Nakano M, Shikama N, Saigenji K, Ishihara K (2008) Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol 43(5):531–537CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Saegusa Y, Ichikawa T, Iwai T, Goso Y, Okayasu I, Ikezawa T, Shikama N, Saigenji K, Ishihara K (2008) Changes in the mucus barrier of the rat during 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol 43(1):59–65CrossRefPubMed Saegusa Y, Ichikawa T, Iwai T, Goso Y, Okayasu I, Ikezawa T, Shikama N, Saigenji K, Ishihara K (2008) Changes in the mucus barrier of the rat during 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol 43(1):59–65CrossRefPubMed
32.
Zurück zum Zitat Saltz L, Shimada Y, Khayat D (1996) CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 32A(Suppl 3):S24–S31CrossRefPubMed Saltz L, Shimada Y, Khayat D (1996) CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 32A(Suppl 3):S24–S31CrossRefPubMed
33.
Zurück zum Zitat Saltz LB (2003) Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 1(1):35–46 (discussion 38–41, 45–36) PubMed Saltz LB (2003) Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 1(1):35–46 (discussion 38–41, 45–36) PubMed
34.
Zurück zum Zitat Sanguinetti A, Santini D, Bonafe M, Taffurelli M, Avenia N (2015) “Interleukin-6 and pro inflammatory status in the breast tumor microenvironment”. World J Surg Oncol 13:129CrossRefPubMedPubMedCentral Sanguinetti A, Santini D, Bonafe M, Taffurelli M, Avenia N (2015) “Interleukin-6 and pro inflammatory status in the breast tumor microenvironment”. World J Surg Oncol 13:129CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Savarese DM, Hsieh C, Stewart FM (1997) Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 15(8):2981–2995CrossRefPubMed Savarese DM, Hsieh C, Stewart FM (1997) Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 15(8):2981–2995CrossRefPubMed
36.
Zurück zum Zitat Sonis ST, Costa JW Jr, Evitts SM, Lindquist LE, Nicolson M (1992) Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 74(6):749–755CrossRefPubMed Sonis ST, Costa JW Jr, Evitts SM, Lindquist LE, Nicolson M (1992) Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 74(6):749–755CrossRefPubMed
37.
Zurück zum Zitat Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025CrossRefPubMed Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025CrossRefPubMed
38.
Zurück zum Zitat Specian RD, Oliver MG (1991) Functional biology of intestinal goblet cells. Am J Physiol 260(2 Pt 1):C183–C193CrossRefPubMed Specian RD, Oliver MG (1991) Functional biology of intestinal goblet cells. Am J Physiol 260(2 Pt 1):C183–C193CrossRefPubMed
39.
Zurück zum Zitat Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, Yeoh AS, Al-Dasooqi N, Keefe DM (2009) Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 90(5):489–499CrossRefPubMedPubMedCentral Stringer AM, Gibson RJ, Bowen JM, Logan RM, Ashton K, Yeoh AS, Al-Dasooqi N, Keefe DM (2009) Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 90(5):489–499CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Hamilton J, Keefe DM (2009) Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 234(4):430–441CrossRef Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Hamilton J, Keefe DM (2009) Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 234(4):430–441CrossRef
41.
Zurück zum Zitat Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM (2008) Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 7(12):1919–1925CrossRefPubMed Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM (2008) Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 7(12):1919–1925CrossRefPubMed
42.
Zurück zum Zitat Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Laurence J, Keefe DM (2009) Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol 64(1):123–132CrossRefPubMed Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Laurence J, Keefe DM (2009) Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol 64(1):123–132CrossRefPubMed
43.
Zurück zum Zitat Verburg M, Renes IB, Meijer HP, Taminiau JA, Buller HA, Einerhand AW, Dekker J (2000) Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol Gastrointest Liver Physiol 279(5):G1037–G1047CrossRefPubMed Verburg M, Renes IB, Meijer HP, Taminiau JA, Buller HA, Einerhand AW, Dekker J (2000) Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol Gastrointest Liver Physiol 279(5):G1037–G1047CrossRefPubMed
44.
Zurück zum Zitat Wadler S, Benson AB 3rd, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E (1998) Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16(9):3169–3178CrossRefPubMed Wadler S, Benson AB 3rd, Engelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E (1998) Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16(9):3169–3178CrossRefPubMed
45.
Zurück zum Zitat Yamamoto H, Ishihara K, Takeda Y, Koizumi W, Ichikawa T (2013) Changes in the mucus barrier during cisplatin-induced intestinal mucositis in rats. Biomed Res Int 2013:276186PubMedPubMedCentral Yamamoto H, Ishihara K, Takeda Y, Koizumi W, Ichikawa T (2013) Changes in the mucus barrier during cisplatin-induced intestinal mucositis in rats. Biomed Res Int 2013:276186PubMedPubMedCentral
Metadaten
Titel
Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model
verfasst von
Daniel Thorpe
Masooma Sultani
Andrea Stringer
Publikationsdatum
27.02.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 5/2019
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-019-03787-5

Weitere Artikel der Ausgabe 5/2019

Cancer Chemotherapy and Pharmacology 5/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.